EyeGene Inc

EyeGene Inc. is a South Korean biotechnology company engaged in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases. Its pipeline includes EG-Mirotin (Phase 2a completed for diabetic retinopathy), EG-Decorin (Phase 2 completed for pressure ulcers and wound healing), and EG-Myocin (Phase 2 completed for myocardial ischemia/reperfusion injury). The company also develops EG-HZ (Phase 1 completed for herpes zoster), EG-HPV (Phase 1 completed for cervical cancer), EG-COVID (Phase 1 for COVID), and EG-TB (preclinical for a tuberculosis vaccine), and offers vitalDB. Founded in 2000, EyeGene is headquartered in Seoul, South Korea.